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SOUHRN
Úvod: Fibrilace síní (FS) je celosvětově nejčastější formou arytmie, která postihuje přibližně 33 milionů je-
dinců. Antikoagulanciem volby v prevenci cévní mozkové příhody u jedinců s FS je již dlouho warfarin. 
Několik velkých studií prokázalo, že nová (přímá) perorální antikoagulancia (non-vitamin K antagonist oral 
anticoagulant, NOAC) mají z hlediska bezpečnosti a účinnosti řadu předností, jako například fi xní dávku 
a předvídatelnější farmakokinetiku.
Metody: Naše studie, provedená v lotyšském kardiocentru Fakultní nemocnice Pauls Stradins (Pauls Stradins 
Clinical University Hospital, Latvian Centre of Cardiology), probíhala od října 2015 do června 2017. Do studie 
bylo zařazeno celkem 356 pacientů, u nichž byla provedena elektrická kardioverze (EKV).
Výsledky: Jeden rok po EKV užívalo 27,5 % pacientů warfarin, 33,7 % pacientů NOAC, zatímco 38,8 % jich 
neužívalo žádná perorální antikoagulancia. Devět (2,5 %) pacientů, kteří se studie zúčastnili, v následujícím 
roce zemřelo. Celkem u osmi pacientů (2,2 %) došlo k významnému krvácení a tři pacienti (0,8 %) prodě-
lali nefatální ischemickou cévní mozkovou příhodu. Incidence nefatální ischemické cévní mozkové příhody 
u pacientů užívajících warfarin byla 2 %, přičemž u pacientů užívajících NOAC nebyla žádná taková příhoda 
zaznamenána (p = 0,20). Incidence významného krvácení byla 5,1 % versus 2,5 % ve skupinách s warfarinem, 
resp. NOAC (p = 0,12). 
Závěry: Ve srovnání s podobnými studiemi prokázala naše studie nízkou incidenci ischemických cévních moz-
kových příhod a významného krvácení i nízkou celkovou mortalitu. Jeden rok po EKV se užívání warfarinu 
snížilo o 2,8 % (p = 0,63) a v případě rivaroxabanu a dabigatranu o 17,5 % (p = 0,001), resp. 17,4 % (p = 
0,001). Naše studie tak prokázala, že NOAC představují bezpečnou a účinnou alternativu k warfarinu.
© 2021, ČKS.
ABSTRACT
Introduction: Atrial fi brillation (AF) is the most common arrhythmia in the world, affecting around 33 million 
people. Warfarin has been the anticoagulant of choice for the prevention of ischemic stroke in AF patients 
for a long time. Several large studies have shown that non-vitamin K antagonist oral anticoagulants (NOACs) 
offer numerous advantages regarding safety and effectiveness, such as fi xed dose and more predictable 
pharmacokinetics.
Methods: The study was conducted at Pauls Stradins Clinical University Hospital, Latvian Centre of Cardiol-
ogy. The study took place from October 2015 to June 2017. A total of 356 patients who had undergone 
electrical cardioversion (ECV) was included in this study.
 Results: One year after ECV, 27.5% of patients used warfarin, 33.7% of patients used NOACs, whereas 38.8% 
did not use any oral anticoagulants. Nine (2.5%) of the patients who participated in the study died during 
the following year. Overall, eight patients (2.2%) suffered from signifi cant bleeding and three patients 
(0.8%) had a non-fatal ischemic stroke. The rate of non-fatal ischemic stroke in patients who used warfarin 
was 2% and no cases were observed in patients who used NOACs (p = 0.20). The rate of signifi cant bleeding 
was 5.1% versus 2.5% in warfarin and NOAC groups, respectively (p = 0.12). 
 Conclusions: Compared with similar studies, our study showed a low rate of ischemic stroke and signifi cant 
bleeding, and a low total death rate. One year after ECV, the use of warfarin decreased by 2.8% (p = 0.63), 
the use of rivaroxaban and dabigatran decreased by 17.5% (p = 0.001) and 17.4% (p = 0.001). The study 
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Introduction
Atrial fi brillation (AF) is the most common arrhythmia in 
the world affecting around 33 million people. It is estima-
ted that by 2030 there will be 20 million patients with AF 
in Europe.1,2
Patients with AF have a fi ve times greater risk of su-
ffering from stroke and an increased risk of myocardial 
infarction, heart failure and death. Moreover, AF creates 
large economic burden due to its rapidly increasing pre-
valence and incidence.3,4
Rhythm and rate control are the two basic principles of 
AF treatment. Regarding mortality and cardiovascular di-
sease, rate control is similar to rhythm control. Accordin-
gly, rate control is often recommended as the fi rst choice 
for symptomatic AF patients. However, many patients 
are symptomatic even with lower heart rate, therefore 
electrical cardioversion (ECV) or pharmacological cardio-
version are offered to these patients as the next step. In 
general, ECV is a safe method for restoring sinus rhythm. 
However, without adequate anticoagulation, the post-
-procedure risk of cardioembolic events is 57%. If an epi-
sode of AF persists for more than 48 hours or the durati-
on of episode is unknown, anticoagulants are considered 
mandatory before cardioversion. Due to increased peri- 
and post-procedural thromboembolic risk, the European 
Society of Cardiology guidelines recommend that antico-
agulant therapy should be started at least three weeks 
before and continued four weeks after cardioversion.5–7
Historically, warfarin has been the anticoagulant of 
choice for the prevention of ischemic stroke in AF pati-
ents. However, several large-scale studies have shown 
that non-vitamin K antagonist oral anticoagulants 
(NOACs) rivaroxaban, dabigatran and apixaban offer nu-
merous advantages regarding safety and effectiveness. In 
contrast to warfarin, they have a fi xed dose, more predic-
table pharmacokinetics, fewer interactions with food and 
other medications, and no need for controlling coagulati-
on parameters. Based on these factors, NOACs are a safe 
and suitable alternative to warfarin for thromboembolic 
prophylaxis in patients with non-valvular AF.8–12
The goal of the study was to determine the most fre-
quently prescribed anticoagulants and their usage in the 
patient population of the study. In addition, safety of the 
respective medications and thromboembolic event rate 
one year after ECV was evaluated.
Methods
Study design and patients
The study was conducted at Pauls Stradins Clinical Uni-
versity Hospital, Latvian Centre of Cardiology from Octo-
ber 2015 to June 2017. A total of 356 patients who had 
undergone ECV were included in this study. Patients were 
admitted with AF, which was confi rmed with an ECG ca-
rried out by a general practitioner, cardiologist, or emer-
gency medical services personnel. Another ECG was per-
formed in the ward where the patient was hospitalized.
Study inclusion criteria were age ≥18 years, confi rmed 
AF in a 12-lead ECG, and ECV during hospitalization. Pati-
ents were excluded if their life expectancy after ECV was 
less than 12 months or if atrial fi brillation spontaneously 
reverted to sinus rhythm.
An anonymous patient questionnaire was used to co-
llect the patient demographic data, information about 
hospitalization, duration of arrhythmia, medication used 
for rhythm control and anticoagulation, and history of 
electrical or pharmacological cardioversion. Information 
about comorbidities and ECV results was obtained from 





-VASc score was calculated for each 
patient.
Patients also participated in a phone survey one year 
after hospitalization. The following information was co-
llected: number of hospitalizations during the previous 
year and reasons for hospitalization, medication used 
for heart rhythm and rate control, medication used for 
thromboembolic prophylaxis, medication side effects (sig-
nifi cant bleeding etc.). Signifi cant bleeding was defi ned 
as bleeding events, including gastrointestinal bleeding, 
haemorrhagic strokes, other intracranial bleeding events 
and bleeding at other sites that requires hospitalization.
In the case of the patient death, the relatives were 
asked to provide detailed information about the cause of 
death and the medications used.
The study was approved by the Ethics Committee of 
Riga Stradins University. All patients received informative 
materials with the description of the study and all pati-
ents gave written consent after familiarizing themselves 
with the description.
Statistical methods
All data obtained during this study were processed with 
Microsoft Excel 365 and IBM SPSS Statistics 22.0. Descrip-
tive statistical methods were used to characterize patient 
parameters: summary tables with columns, bar graphs or 
histograms, mean arithmetic and standard deviation. Un-
paired t-test or Mann-Whitney test were used to compare 
continuous variables, and Pearson 2 or Fisher’s exact test 
(if the number of expected cases was n < 5 in one of the 
columns in the table) were used to compare categorical 
variables in the study subgroups, as appropriate.
The McNemar test was conducted to compare the use 
of anticoagulants upon leaving the hospital and one year 
later. All p-values were considered statistically signifi cant 
at a 5% confi dence level.
Results
 The mean age of patients was 65.3 (±10.6) years; 55.1% of 
patients were male. The mean characteristics of patients 
can be seen in Table 1. ECV was successful and sinus rhy-
thm was restored in 325 (91.3%) patients. In patients with 
an AF episode lasting 48 hours or more or an unknown 
duration, the frequency of sinus rhythm restoration was 
lower, compared with patients with AF episode of less 
than 48 hours: 90.8% and 96.8%, respectively, p = 0.023. 
A total of 185 (51.9%) patients had at least one episode 
of AF over a period of one year.
Following ECV, warfarin was prescribed to 108 (30.3%) 
patients, NOACs were prescribed to 244 (68.6%) patients, 
106 (29.8%) were prescribed dabigatran, and 138 (38.8%) 
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used rivaroxaban, while 138 (38.8%) did not use any oral 
anticoagulants. Within one year after ECV, the use of 
warfarin decreased by 2.8% (p = 0.63), the use of rivar-
oxaban and dabigatran decreased by 17.5% (p = 0.001) 
and 17.4% (p = 0.001), respectively (Fig. 1). At follow-up, 
15 (13.9%) patients who were prescribed warfarin had 
switched to NOACs and 47 (19.2%) patients who initially 
received NOACs had switched to warfarin.
Patients who used warfarin were signifi cantly older 
than patients who used NOACs (68.1±1.3 vs. 63.2±1.1, p 
= 0.003) and had more risk factors for thromboembolic 
events: female sex (49.0% vs. 41.3% p = 0.028), chronic 
heart failure (60.4% vs. 45.4%, p = 0.019), diabetes mel-
litus (26.6% vs. 13.2%, p = 0.003) (Table 2).
No peri-procedural cardioembolic events were ob-
served in this study.
Nine (2.5%) patients who participated in the study 
died during the following year. Three patients died from 
stroke, one from complications arising from myocardial 
Table 1 – Patient baseline characteristics
Total, n (%)
Age (mean±SD) 65.3±10.6
Age >65 years 208 (58.4%)
Sex, male 196 (55.1%)
Body mass index (kg/m2) (mean±SD) 31.5±5.7
History of arterial hypertension 241 (67.7%)
History of heart failure 182 (51.1%)
History of diabetes mellitus 62 (17.4%)
Prior myocardial infarction 42 (11.8%)
Prior stroke 37 (10.4%) 
Implanted pacemaker 26 (7.3%)
History of radiofrequency catheter ablation 19 (5.3%)
History of AF 188 (52.8%)
Duration of paroxysm
<48 h 31 (8.7%)
>48 h 253 (71.1%)
Unknown time 72 (20.2%)






    0 19 (5.3%)
    1 54 (15.2%)
    ≥2 283 (79.5%)

















p-value = 0.001 p-value = 0.001p-value = 0.63 








At discharge 1 year follow up




-VASc scores for warfarin 
and NOACs groups
Warfarin NOAC p-value
Mean age 68.1 63.2 0.003
Sex, female 49.0% 41.3% 0.028
Heart failure 60.4% 45.4% 0.019
Hypertension 82.6% 77.8% 0.47
Age >75 years 17.7% 14.2% 0.57
Diabetes mellitus 26.6% 13.2% 0.003
Vascular disease 11.3% 9.2% 0.65
Stroke 8.2% 13.3% 0.27
patients were prescribed rivaroxaban. One year after ECV, 
98 (27.5%) patients used warfarin, 120 (33.7%) patients 
used NOACs, 44 (12.4%) used dabigatran and 76 (21.3%) 
On -year follow-up
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infarction, and fi ve patients died from non-cardiac dis-
eases. Two of the patients who died from ischemic stroke 
used anticoagulants (warfarin and rivaroxaban) and one 
patient did not use any medication for antithrombotic 
prophylaxis. 
The rate of signifi cant bleeding and non-fatal ischemic 
stroke was low among the patients who participated in 
this study, without signifi cant differences between the 
warfarin and NOAC groups. The rate of non-fatal isch-
emic stroke in patients who used warfarin was 2% (two 
cases), and no cases of non-fatal ischemic stroke were ob-
served in patients who used NOACs, p = 0.20. The rate of 
signifi cant bleeding was 5.1% (fi ve cases) vs. 2.5% (three 
cases) in warfarin and NOAC groups, respectively; p = 0.12 
(Fig. 2). 
For 70.3% (n = 97) of patients who did not use any oral 





-VASc score was 2 or higher. Out of all patients 
who did not use any oral anticoagulants, one had had 
ischemic stroke (0.8%) and none of the patients men-
tioned any episodes of signifi cant bleeding. 
Discussion
Compared with similar studies, the present study showed 
a low rate of ischemic stroke, signifi cant bleeding, as well 
as a low total death rate in the patient population of the 
study.13–15 
 During the year following discharge from hospital, 
three patients died from ischemic stroke; two of them 
were taking anticoagulants. One of the patients used 
warfarin and the other one used rivaroxaban. Both pa-





-VASc score was ≥2. The European Society of Car-
diology guidelines state that optimal international nor-
malised ratio (INR) in patients with nonvalvular AF is 2.0–
3.0. In some patients, the target INR could be diffi cult to 
reach due to several factors, such as interactions with oth-
er medications and diet-related errors.13 A meta-analysis 
by Shin et al. showed that patients taking warfarin were 
in the therapeutic range about 60% of the time.16 Unfor-
tunately, there are no accurate data available whether 
a patient had achieved the target INR. We assume that 
patient’s INR was below therapeutic range and this may 
be the reason for fatal outcome.
Warfarin might not be the only culprit here, as the sec-
ond patient who died of ischemic stroke was taking rivar-
oxaban. Studies show that oral bioavailability of a 10 mg 
tablet dose of rivaroxaban is up to 80–100% irrespective 
of fasting or fed conditions, unlike the 20 mg rivaroxaban 
tablet, whose maximum bioavailability under fasting con-
ditions is only 66%.17 25% of patients participating in the 
present study took rivaroxaban on a fasting condition. 
This in turn increases the risk of thromboembolic events. 
One year after electrical cardioversion, three (0.8%) 
patients suffered non-fatal ischemic stroke. This rate is 
lower than reported in the study by Apostolakis et al., 
where clinical outcomes six months after electrical cardio-
version were analysed, showing a 0.9% rate of stroke and 
transient ischemic attack.13 A different study, conducted 
by Shin et al, reported that the rate of stroke one month 
after electrical cardioversion was 0.5% in their patient 
group.15 Our study shows a low stroke rate, even in pa-
tients who were not taking anticoagulants. This could be 
attributed to a low number of patients participating in 
study and a relatively short follow-up period. A limitation 
of the follow-up was that patients were not inquired for 
how long they stopped taking oral anticoagulants after 
electrical cardioversion. Some patients may have stopped 
their oral anticoagulant therapy shortly before the fol-
low-up.
The rate of signifi cant bleeding in this study was 2.2%. 
Compared with Shin et al, who reported a 0.5% rate of 
signifi cant bleeding during the one month follow-up af-
ter electrical cardioversion,15 and Apostolakis et al, who 
reported a 0.8% rate of signifi cant bleeding six months 
after electrical cardioversion,13 our study shows a low rate 
of signifi cant bleeding one year after electrical cardiover-
sion. Further examining the study results, we can see that 
NOACs are a safe and effective alternative to warfarin. 
Signifi cant bleeding and ischemic stroke rates were lo-
wer in the NOAC group than in the warfarin group. Our 
results are similar to data reported in a study by Femia 
et al., although, compared to NOACs, warfarin showed 
a non-signifi cantly higher rate of stroke (1.8% vs. 0.6%) 
as well as a higher rate of signifi cant bleeding (3.6% vs. 
1.7%).14
 The study results show that the number of warfarin 
users didn’t change signifi cantly, whereas NOAC usage 
decreased one year after electrical cardioversion. Most 
of the patients (38.9%) who discontinued the use of NO-
ACs did not switch to any other anticoagulants, where-
as 19.2% of patients switched to warfarin. Studies have 
shown that NOACs offer numerous advantages regarding 
safety and effectiveness, such as fi xed dose, more predic-
table pharmacokinetics, fewer interactions with food and 
other medications, and no need to control coagulation 
parameters. The present study found that adherence to 
oral anticoagulant therapy was lower in patients taking 
NOACs. In a study conducted by Barret et al., approxima-
tely 2% of participants switched from NOACs to warfarin; 
the most common reasons for switching where bleeding 











Major bleeding Ischemic stroke
Warfarin NOAC
p-value = 0.20p-value = 0.12 
 Fig. 2. – The incidence of non-fatal ischemic stroke and major bleed-
ing events in patients treated with warfarin and non-vitamin K an-
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nal deterioration.18 The fact that many patients stopped 
taking NOACs and some switched to warfarin could be 
explained by various factors associated with the patient, 
general practitioner and medication price differences. At 
the time of this study, NOACs were not included in the 
government reimbursement system, therefore many pa-
tients, especially those with low income, could not afford 
NOACs. The large price difference between warfarin and 
NOACs was the main reason why so many patients discon-
tinued the use of NOACs. 
The main limitation of the study is the fact that we 
don’t know the ratio of patients with and without atrial 
fi brillation at follow-up and that the patients were not 
inquired at what point they stopped taking oral antico-
agulants following electrical cardioversion. Therefore is-
chemic and bleeding event rate in patients who didn’t 
receive OAK should be interpreted with caution.
Conclusions
The study shows a low rate of ischemic stroke and signi-
fi cant bleeding, and a low death rate. The usage of war-
farin did not change one year after ECV, whereas NOAC 
usage decreased signifi cantly. NOACs are a safe and 
effective alternative to warfarin. 
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